» Articles » PMID: 30682092

Retrospective Evaluation of Nitrofurantoin and Pivmecillinam for the Treatment of Lower Urinary Tract Infections in Men

Overview
Journal PLoS One
Date 2019 Jan 26
PMID 30682092
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study aimed to retrospectively assess the clinical outcome with nitrofurantoin and pivmecillinam for lower urinary tract infections (UTI) in men. Patients treated with trimethoprim were also included for comparison.

Methods: All prescriptions of the study antibiotics to adult men in Uppsala County, Sweden, during 2012 were extracted. Data on patient characteristics, therapy, clinical outcome and microbiological results were obtained from the electronic medical records. The relative impact of antibiotic therapy, patient factors and pathogens on clinical outcome was assessed with univariate logistic regression using a 95% confidence interval (CI).

Results: 832 prescriptions were identified, and 171 patients treated with nitrofurantoin (n = 69), pivmecillinam (n = 57) and trimethoprim (n = 45) met the inclusion criteria. Treatment failure occurred in one patient treated with nitrofurantoin and in four patients treated with pivmecillinam. New prescriptions of UTI antibiotics and relapse within 3 months after completion of therapy were more frequent with nitrofurantoin (34% and 15%) and pivmecillinam (30% and 17%) than trimethoprim (22 and 7%). However, these differences were not statistically significant and substantial heterogeneity was noted between the treatment groups. Urinary tract catheterization was associated with a higher risk for new antibiotic prescriptions (OR 2.34, 95% CI 1.14-4.80; P = 0.022) and prostate cancer was associated with a higher incidence of relapse (OR 3.01, 95% CI 1.09-8.29; P = 0.042).

Conclusions: The clinical outcome with nitrofurantoin and pivmecillinam was acceptable in comparison with the results of previous studies. These antibiotics are suitable for empirical treatment of lower UTI in men considering their high activity against Escherichia coli and limited impact on the intestinal microbiota.

Citing Articles

Bacterial growth and antimicrobial resistance in urinary isolates among men with lower UTI in Swedish primary healthcare: retrospective data over a 4 year period.

Kornfalt Isberg H, Sundqvist M, Melander E, Beckman A, Hedin K JAC Antimicrob Resist. 2024; 7(1):dlae214.

PMID: 39734489 PMC: 11670775. DOI: 10.1093/jacamr/dlae214.


Acute Cystitis in a Transfeminine Patient: Assessment and Treatment of Urinary Tract Symptoms.

Senda J, Phillippi J J Midwifery Womens Health. 2024; 70(1):163-168.

PMID: 39450671 PMC: 11803489. DOI: 10.1111/jmwh.13696.


Treatment, outcomes and characterization of pathogens in urinary tract infections caused by ESBL-producing Enterobacterales: a prospective multicentre study.

Montelin H, Camporeale A, Hallgren A, Angelin M, Hogvall J, Ostholm Balkhed A J Antimicrob Chemother. 2024; 79(3):531-538.

PMID: 38197416 PMC: 10904723. DOI: 10.1093/jac/dkad402.


Acute cystitis in men- a nationwide study from primary care: antibiotic prescriptions, risk factors, and complications.

Saetre H, Skow M, Vik I, Hoye S, Emilsson L BJGP Open. 2024; 8(2).

PMID: 38191188 PMC: 11300979. DOI: 10.3399/BJGPO.2023.0207.


Definitions of Urinary Tract Infection in Current Research: A Systematic Review.

Bilsen M, Jongeneel R, Schneeberger C, Platteel T, Van Nieuwkoop C, Mody L Open Forum Infect Dis. 2023; 10(7):ofad332.

PMID: 37426954 PMC: 10323732. DOI: 10.1093/ofid/ofad332.


References
1.
Ulleryd P . Febrile urinary tract infection in men. Int J Antimicrob Agents. 2003; 22 Suppl 2:89-93. DOI: 10.1016/s0924-8579(03)00228-0. View

2.
Flores-Mireles A, Walker J, Caparon M, Hultgren S . Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5):269-84. PMC: 4457377. DOI: 10.1038/nrmicro3432. View

3.
Nicolle L . Best pharmacological practice: urinary tract infections. Expert Opin Pharmacother. 2003; 4(5):693-704. DOI: 10.1517/14656566.4.5.693. View

4.
Ingalsbe M, Wojciechowski A, Smith K, Mergenhagen K . Effectiveness and safety of nitrofurantoin in outpatient male veterans. Ther Adv Urol. 2015; 7(4):186-93. PMC: 4580093. DOI: 10.1177/1756287215581556. View

5.
Pulcini C, Bush K, Craig W, Frimodt-Moller N, Grayson M, Mouton J . Forgotten antibiotics: an inventory in Europe, the United States, Canada, and Australia. Clin Infect Dis. 2011; 54(2):268-74. DOI: 10.1093/cid/cir838. View